NO20064981L - Oksadiazolonderivater som PPAR delta agonister - Google Patents

Oksadiazolonderivater som PPAR delta agonister

Info

Publication number
NO20064981L
NO20064981L NO20064981A NO20064981A NO20064981L NO 20064981 L NO20064981 L NO 20064981L NO 20064981 A NO20064981 A NO 20064981A NO 20064981 A NO20064981 A NO 20064981A NO 20064981 L NO20064981 L NO 20064981L
Authority
NO
Norway
Prior art keywords
disorders
ppar
agonists
participate
compounds
Prior art date
Application number
NO20064981A
Other languages
English (en)
Inventor
Corinne Terrier
Baptiste Ronan
Stefanie Keil
Jean Merrill
Karen Chandross
Jochen Goerlitzer
Wolfgang Wendler
Daniel G Mcgarry
Maike Glien
Patrick Bernardelli
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20064981L publication Critical patent/NO20064981L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives oksadiazoloner og deres fysiologisk akseptable salter og fysiologisk funksjonelle derivater som viser PPAR 5 aktivitet. Det beskrives forbindelser med formel (I) der restene er som definert og deres fysiologisk akseptable salter samt fremgangsmåter for deres fremstilling. Forbindelsene er egnet for terapi og/eller prevensjon av forstyrrelser av fettsyremetabolisme og glukoseutnyttelsesforstyrrelser så vel som forstyrrelser der insulinresistens er involvert, neurodegenerative sykdommer og/eller demyelinerende forstyrrelser av sentral- og perifernervesystemet og/eller neurologiske forstyrrelser som involverer neuroinflammatoriske prosesser og/eller annen perifer neuropati.
NO20064981A 2004-04-01 2006-10-31 Oksadiazolonderivater som PPAR delta agonister NO20064981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (en) 2004-04-01 2004-04-01 Oxadiazolones, processes for their preparation and their use as pharmaceuticals
PCT/EP2005/002950 WO2005097786A1 (en) 2004-04-01 2005-03-19 Oxadiazolone derivatives as ppar delta agonists

Publications (1)

Publication Number Publication Date
NO20064981L true NO20064981L (no) 2006-12-28

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064981A NO20064981L (no) 2004-04-01 2006-10-31 Oksadiazolonderivater som PPAR delta agonister

Country Status (38)

Country Link
US (3) US20070179191A1 (no)
EP (3) EP1586573B1 (no)
JP (1) JP2007530612A (no)
KR (1) KR20060135857A (no)
CN (1) CN100582104C (no)
AR (1) AR050576A1 (no)
AT (1) ATE435225T1 (no)
AU (1) AU2005231916A1 (no)
BR (1) BRPI0509517A (no)
CA (1) CA2561627A1 (no)
CR (1) CR8572A (no)
CY (1) CY1109370T1 (no)
DE (2) DE602004004631D1 (no)
DK (1) DK1740583T3 (no)
DO (1) DOP2005000051A (no)
EC (1) ECSP066892A (no)
ES (1) ES2329484T3 (no)
GT (1) GT200500028A (no)
HK (1) HK1100408A1 (no)
HR (1) HRP20090493T1 (no)
IL (1) IL178056A0 (no)
MA (1) MA28495B1 (no)
MY (1) MY142431A (no)
NO (1) NO20064981L (no)
PA (1) PA8628701A1 (no)
PE (1) PE20060323A1 (no)
PL (1) PL1740583T3 (no)
PT (1) PT1740583E (no)
RS (1) RS51186B (no)
RU (1) RU2374243C2 (no)
SI (1) SI1740583T1 (no)
SV (1) SV2006002071A (no)
TN (1) TNSN06317A1 (no)
TW (1) TW200602342A (no)
UA (1) UA84203C2 (no)
UY (1) UY28837A1 (no)
WO (1) WO2005097786A1 (no)
ZA (1) ZA200606870B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
AU2006299090A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Derivatives of 2 -aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
WO2007039178A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
US9717719B2 (en) 2006-09-08 2017-08-01 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2010000353A1 (en) * 2008-06-09 2010-01-07 Sanofi-Aventis Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
CA2727373A1 (en) * 2008-06-09 2009-12-17 Sanofi-Aventis Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
WO2009149819A1 (en) * 2008-06-09 2009-12-17 Sanofi-Aventis Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
SI3135672T1 (sl) * 2008-10-10 2020-07-31 Vm Discovery, Inc. Sestavki in postopki za zdravljenje motenj, bolečin in drugih bolezni povezanih z uporabo alkohola
CA2738630A1 (en) 2008-10-10 2010-04-15 Dara Biosciences, Inc. Methods for treating or preventing pain using spicamycin derivatives
MX2012001107A (es) * 2009-08-05 2012-03-26 Daiichi Sankyo Co Ltd Derivado de amida.
JP5546543B2 (ja) * 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) * 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CN1158290C (zh) 1996-01-17 2004-07-21 诺沃挪第克公司 稠合1,2,4-噻二嗪与稠合1,4-噻嗪衍生物、其制备方法及用途
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
BR0010126A (pt) 1999-04-28 2002-02-26 Aventis Pharma Gmbh Derivados de ácido tri-arìlico como ligandos receptores de ppar
BR0010605A (pt) 1999-04-28 2002-02-13 Aventis Pharma Gmbh Derivados ácidos de di-aril como ligantes de receptores ppar
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
ATE302754T1 (de) 1999-09-01 2005-09-15 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
SK7652002A3 (en) 1999-12-03 2002-11-06 Astrazeneca Ab Crystalline form of (s)-2-ethoxy-3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
PT2266665T (pt) 2000-03-31 2016-07-07 Royalty Pharma Collection Trust Método para o melhoramento da sinalização de ilhéus na diabetes mellitus e para a sua prevenção
IL152224A0 (en) 2000-04-25 2003-05-29 Kyorin Seiyaku Kk Stable crystals of thiazolidinedione derivative and process for the preparation thereof
CA2407538C (en) 2000-04-28 2007-01-09 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
DE50102147D1 (de) 2000-06-09 2004-06-03 Aventis Pharma Gmbh Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
ATE349425T1 (de) 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EP1368011A1 (en) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Method for treating ppar gamma mediated diseases
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
EP1448538A1 (en) * 2001-11-15 2004-08-25 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004094394A1 (en) 2003-04-01 2004-11-04 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1613608A1 (en) 2003-04-01 2006-01-11 Eli Lilly And Company Phospholipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
WO2007039178A2 (en) * 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
EP1740583A1 (en) 2007-01-10
TW200602342A (en) 2006-01-16
BRPI0509517A (pt) 2007-09-11
IL178056A0 (en) 2006-12-31
CR8572A (es) 2007-12-04
US20070179191A1 (en) 2007-08-02
EP1740583B1 (en) 2009-07-01
US7709509B2 (en) 2010-05-04
AR050576A1 (es) 2006-11-08
CN100582104C (zh) 2010-01-20
SI1740583T1 (sl) 2009-12-31
DE602004004631D1 (de) 2007-03-22
EP1586573A1 (en) 2005-10-19
EP2083006A1 (en) 2009-07-29
RU2006138498A (ru) 2008-05-10
DK1740583T3 (da) 2009-10-19
PE20060323A1 (es) 2006-03-31
HK1100408A1 (en) 2007-09-21
EP1586573B1 (en) 2007-02-07
MA28495B1 (fr) 2007-03-01
ATE435225T1 (de) 2009-07-15
TNSN06317A1 (en) 2007-12-03
CN1938300A (zh) 2007-03-28
WO2005097786A1 (en) 2005-10-20
ECSP066892A (es) 2006-11-24
RS51186B (sr) 2010-10-31
MY142431A (en) 2010-11-30
RU2374243C2 (ru) 2009-11-27
KR20060135857A (ko) 2006-12-29
UA84203C2 (en) 2008-09-25
PL1740583T3 (pl) 2009-12-31
UY28837A1 (es) 2005-10-31
DOP2005000051A (es) 2005-12-15
AU2005231916A1 (en) 2005-10-20
US20080255212A1 (en) 2008-10-16
JP2007530612A (ja) 2007-11-01
ZA200606870B (en) 2008-04-30
SV2006002071A (es) 2006-01-30
CA2561627A1 (en) 2005-10-20
CY1109370T1 (el) 2014-07-02
GT200500028A (es) 2006-06-09
PA8628701A1 (es) 2006-11-25
HRP20090493T1 (en) 2009-10-31
DE602005015204D1 (de) 2009-08-13
ES2329484T3 (es) 2009-11-26
PT1740583E (pt) 2009-09-16
US20080262052A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
NO20064981L (no) Oksadiazolonderivater som PPAR delta agonister
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO20081682L (no) 4-oksy-N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
NO20081369L (no) Fenyl- og pyridinyl-1,2,4-oksadiazolonderivater, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
US10344002B2 (en) Compositions and methods for treating metabolic disorders
EP2083811B1 (en) Methods of treating down's syndrome, fragile x syndrome and autism
KR20170012449A (ko) 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도
WO2004113270A3 (en) Propionic acid derivatives useful in the treatment of lipid disorders
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
US20170304351A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP6977029B2 (ja) レット症候群を治療するためのプリドピジンの使用
WO2020014504A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
NO20054381L (no) 1,3-substituerte sykloalkylderivater med sure, som oftest heterosykliske grupper, deres fremstilling og deres anvendelse som legemiddel
EP4326268A1 (en) Treatment of cns diseases with sgc stimulators
NO20081675L (no) Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
NO20081368L (no) Derivater av 2-amintiazoler og 2-aminooksazoler, fremgangsmate for fremstilling derav samt deres anvendelse som farmasoytika
NO20081676L (no) Bicykliske aryl-sulfonylsyre[1,3,4]-tiadlazol-2-yl-amlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
NO20054397L (no) Cykloalkylderivater med bioisosteriske karboksylsyregrupper, fremgangsmate for fremstilling av disse og deres anvendelse som legemiddel
NO20055889L (no) 2-etoksy-3-fenylpropansyrederivater for behandling av fettforstyrrelser
MXPA05006409A (es) Uso de l-dopa, de sus derivados y medicamentos comprendiendo estos compuestos para la prevencion de enfermedades psicoticas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application